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Abstract:  The management of coronary patients scheduled for a coronary artery bypass grafting (CABG), who are 
receiving one or more antiplatelet drugs, is plenty of controversies. It has been shown that withdrawal of antiplatelet drugs 
is associated with an increased risk of a thrombotic event, but surgery under an altered platelet function also means an 
increased risk of bleeding in the perioperative period. Because of the conflict recommendations, this review article tries to 
evaluate the outcome of different perioperative antiplatelet protocols in patients with coronary artery disease undergoing 
CABG. 
1. INTRODUCTION 
  The incidence of coronary artery disease (CAD) is high 
and increasing. First treatment of occlusive coronary disease 
involves percutaneous revascularization and many times one 
or more stents placement. Any percutaneous coronary 
intervention causes trauma to the vessel wall, rendering the 
endoluminal surface thrombogenic and thus, dual anti-
platelet therapy (mostly aspirin and clopidogrel) is currently 
recommended [1, 2]. 
  When these patients are scheduled for coronary artery 
bypass grafting (CABG), the traditional recommendation has 
been to stop antiplatelet drugs between 7 to 10 days prior to 
surgery [3]. But, withdrawal of aspirin in patients with CAD 
has been associated with a 2 to 4-fold increase in the risk of 
death and myocardial infarction [4], being the major 
independent predictor of stent occlusion [5, 6]. Thus, the 
anaesthesiologist faces the dilemma of stopping the 
antiplatelet treatment to avoid bleeding and risking 
postoperative stent thrombosis, or to maintain the antiplatelet 
therapy perioperatively to avoid the stent thrombosis, so 
risking major blood loss and increased transfusion rate. 
  We lack scientific evidence on the optimum perioperative 
therapy in such a situation. Because of the conflict 
recommendations, we undertook this systematic review of 
the literature to evaluate the outcome of different 
perioperative antiplatelet protocols in patients with CAD 
undergoing CABG. 
2. MAIN CHARACTERISTICS OF ANTIPLATELET 
DRUGS 
  The well established current indications of antiplatelet 
drugs (APD) are shown in Table 1 [7, 8].  
  All of them are capable to inhibit platelet function, 
particularly activation and subsequent aggregation, although 
they make this effect through different ways showing 
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Table 1.  Recognized Indications of the Antiplatelet Drugs 
 
Indications in Cardiology 
•  Acute myocardial infarction 
•  Acute coronary syndrome 
  - Stable angina 
  - Unstable angina/acute myocardial infarction without Q wave 
•  Percutaneous coronary angioplasty with coronary stent 
•  Atrial fibrillation* 
•  Patients undergoing CABG surgery 
•  Some patients with valvulopathies 
Indications in Neurology 
•  Acute phase of stroke 
•  Secondary prevention of strokes in patients without emboligen 
heart disease 
Other Indications 
•  Patient of valve prosthesis 
•  Emboligen carotid stenosis 
•  Carotid endarterectomy 
•  Patients with Antibodys Antifosfolípidos 
•  Peripheral artheriopaty with or without intermittent claudication 
•  Primary prevention in patients with cardiovascular risk 
(*) In patients of less than 65 years without another associated risk factor. 
 
 
different antiaggregant power (Table 2) [9, 10]. APD can be 
classified into four groups:  
1.  Adenosin diphosphate (ADP) receptor antagonists, 
such as the thienopyridine drugs ticlopidine and 
clopidogrel, which reach their peak of activity after 3-5 
days, producing a prolonged antiaggregant effect (7-10 
days) due to its long  half-life. The inhibitory  effects  of 126    Current Cardiology Reviews, 2009, Vol. 5, No. 2  Ferrandis et al. 
Table  2. Antiaggregant Effect of Some of the Antiplatelet 
Drugs 
 
Drug 
Complete Reversal 
Time (days) 
Antiaggregant Effect  
Adenosin Diphosphate Receptor Antagonists 
Ticlopidine 10-14  High 
Clopidogrel 7-10  High 
GPIIB/IIIA Receptor Antagonists 
Eptifibatide 4  hours  High 
Tirofiban 4  hours  High 
Abciximab 48-72  hours  High 
Inhibitors Of Ciclooxygenase 1 Enzyme (COX-1) 
ASA 7  High 
Piroxicam 7  High 
Indometacin 3  High 
Ketorolac 2  High 
Flurbiprofen 1  High 
Ibuprofen 1  Moderate 
Naproxen 2  Moderate 
Ketoprofen 1  Moderate 
Diclofenac 1  Moderate 
Salsalate <  1  Weak 
Diflunisal <  1  Weak 
Paracetamol <  1  Weak 
Proparacetamol <  1  Weak 
Metamizol <  1  Weak 
Rofecoxib 0  No 
Celecoxib 0  No 
Drugs That Increase The Intraplatelet Levels Of AMPC 
Trifusal 7  High 
Dipyridamole 1  Moderate 
 
clopidogrel could be attained earlier by using 300 or 600 
mg loading dose. Moreover, 600 mg double bolus has 
been shown to achieve greater platelet inhibition than 
conventional single loading doses [11]. 
2.  GPIIb/IIIa receptor antagonists, of exclusively 
intravenous use, which are more powerful, albeit with a 
shorter-lasting action (24 h): eptifibatide, abciximab, 
tirofiban.  
3.  Drugs that increase the intraplatelet levels of AMPc. 
The best known agent in this group is dipyridamole 
(moderate antiaggregant effect lasting about 24 hours). 
Other drugs are the I-2 prostaglandin (epoprostenol) and 
its analog iloprost, both used by intravenous route with a 
brief antiaggregant effect (< 3 h).  
4.  Inhibitors of ciclooxygenase 1 enzyme (COX-1). The 
best known representatives are acetylsalicylic acid 
(ASA) and non-esteroidal anti-inflammatory drugs 
(NSAIDs). ASA is the most deeply studied one and its 
antiaggregant effect takes place with the irreversible 
blockade of COX-1, so its action lasts throughout all the 
life of the platelet (7-10 days). Nevertheless, from the 
third or fourth day usually there is enough number of 
platelets to guarantee suitable haemostasis. The NSAIDs 
also produce inhibition of platelet aggregation by a 
similar mechanism to the ASA, although there are two 
important differences: firstly the blocking effect of the 
COX-1 is reversible, thus once the drug has been 
eliminated from the circulation, the platelet function is 
restored; secondly, there is a great difference between 
the different NSAIDs in their capacity to inhibit COX-1 
and, consequently, in its platelet antiaggregant action. 
  Actually the field of the indications of use of the APD is 
being continuously updated. In cardiologic patients, some 
recent questions of development of the APD deserved to be 
highlighted:  
•  The role of the aspirin in the primary prevention has 
extended its prescription based on related factors of 
cardiovascular and/or neurological risk. Moreover the 
combination of two APD drugs (mainly ASA and 
clopidogrel) in high risk patients is a practice more and 
more extended [9]. 
•  Dual antiplatelet therapy has to be maintained at least 12 
months after drug eluting stent placement and elective 
surgery postponed; if surgery is necessary, at least ASA 
should be maintained throughout the periperative period 
and the patient operated under its antiaggregant effect 
[12]. Probably, in this patient a specific protocol of 
antiaggregation in type, combination and duration of 
APD need to be applied [13, 14]. 
•  The interindividual response to the APD is evident and 
it does not seem that a valid universal pattern of 
antiaggregation for all the patients exists. 
  Then, we face different type of patients who benefit from 
antiplatelet therapy (Table 3) [15, 16]. From our point of 
view, we could distinguish two groups: patients with chronic 
treatment who are scheduled for cardiac surgery and patients 
who require urgent surgery, most of them with double 
antiaggregation. 
3. CARDIOVASCULAR RISK AFTER ANTIPLATE-
LET DRUGS WITHDRAWAL 
  The antiplatelet therapy in patients at high risk of 
occlusive vascular events reduce the combined outcome of 
any serious vascular event by about one quarter, non-fatal 
myocardial infarction by one third, non-fatal stroke by one 
quarter, and vascular mortality by one sixth (with no 
apparent adverse effect on other death) [17]. Aspirin has 
been the most widely studied APD, with doses of 75-150 mg 
daily at least as effective as higher daily doses. Keeping 
patients on aspirin prior to surgery may help to attenuate the 
inflammatory response during the operative period and may 
also reduce cardiovascular events while awaiting surgery 
[18]. 
  As we have previously described, the platelet inhibition 
achieved with aspirin, although irreversible for target 
platelets, lasts until a significant pool of new platelets is 
produced. Nevertheless, a complete recovery of platelet 
aggregation has been observed by day 3 (in 50% healthy Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery  Current Cardiology Reviews, 2009, Vol. 5, No. 2    127 
young men) [19] which seems due in part of a biological 
platelet aggregation “rebound phenomenon”. In fact, after 
aspirin discontinuation, the recovery of cyclooxigenase 
activity may occur rapidly, with a heterogeneous synthesis of 
thromboxane A2 by fresh platelets [20], which may have 
possible hazardous effects in patients with cardiovascular 
disease [21]. Nevertheless, none of the guidelines support the 
assessment of platelet reactivity by using point-of-care 
devices. 
  Many studies have been recently published describing the 
cardiovascular risk of perioperative APD withdrawal, most 
of them in non-cardiac surgery, but we did not find any study 
comparing the cardiovascular risks of preprocedural APD 
withdrawal directly against APD continuation. Instead of it, 
we collect some studies that report the frequency of APD 
(aspirin) withdrawal preceding acute cardiovascular 
syndrome (Table 4) [4, 22-24].  
  Talking about clopidogrel, most guidelines would 
recommend cessation for 5-7 days before surgery. The 
CURE study [25] and its sub-analyses show that cessation of 
clopidogrel in these patients and for this time period is 
associated with a 1% increase in the risk of myocardial 
infarction. In non-surgical patients, with acute coronary 
artery syndrome, the first 90-day interval after stopping 
treatment with clopidogrel was associated with a 
significantly higher risk of adverse events (incidence rate 
ratio of 1.98) [26]. 
4. BLEEEDING RISK WITH PERIOPERATIVE 
TREATMENT OF ANTIPLATELET DRUGS 
  There are many clinical studies comparing peri-
procedural-bleeding risks with and without aspirin. Ex-
cluding studies on cardiac surgery, aspirin multiplied 
baseline-bleeding rate by a factor of 1.5
  [24], although 
mortalities possibly caused by bleeding occurred only after 
transurethral prostatectomy [27] and intracranial neuro-
surgery [28].  
  Focus on cardiac surgery, the results are heterogeneous 
but there seems to have an increase of bleeding with a 
tendency to need more transfusion requirements in patients 
under the effect of aspirin [29-35]. Thus, in a recent 
systematic review of randomized and observational studies 
[36], pre-operative aspirin maintenance was associated with 
a significant increase in the volume of post-operative 
bleeding (mean difference 114 ml) and transfusion 
requirements (mean difference 0.34 units), with not 
significantly difference in the rates of reoperation; with the 
subgroup analysis, the authors conclude that this bleeding 
could be minimized by the use of aspirin doses less than 325 
mg/day. Another metanalysis [37] shows similar results, 
highlighting that the rate of platelet transfusion was similar 
in both groups. 
  Bleeding complications and transfusion requirements 
could be lower if the CABG surgery is performed off-pump, 
and patients under the effect of aspirin seems to be at less 
Table 3.  Recommendations on the Use of Antiplatelet Agents 
 
Clinical Setting  Recommendation  Grade 
Ischaemic heart disease 
Chronic stable angina 
Acute coronary syndrome without ST-segment elevation with PCI 
Without PCI 
Acute myocardial infarction with ST elevation 
Acute myocardial infarction with ST elevation and with primary PCI 
 
Aspirin or clopidogrel (as alternative) 
Aspirin or clopidogrel + aspirin (more effective) 
Aspirin or clopidogrel + aspirin (more effective) 
i.v. GPIIb/IIIa inhibitors  
Aspirin 
i.v. GPIIb/IIIa inhibitors 
 
1A 
1A 
1A 
 
2A 
1A 
1A 
Prior myocardial infarction  Aspirin or clopidogrel (as alternative)  1A 
Elective PCI 
Elective PCI + stent application 
Aspirin 
Clopidogrel or ticlopidine 
i.v.GPIIb/IIIa inhibitors 
1A 
1A 
2A 
PCI: Percutaneous coronary intervention. Grades of recommendation as defined by Guyatt et al. [16]. 
Table 4.  Aspirin Withdrawal Preceding Acute Cardiovascular Syndrome 
 
Studies  
(Author, Year) 
Number of Patients 
Admitted for ACS 
% Patients with Recent 
Withdrawal of APD 
% Withdrawal for Surgery 
Time between Withdrawal 
Aspirin and ACS 
Collet, 2004  1358  73(5.4%)  74.38%  11.9±0.8 
Collet, 2000  475  11(2.3%)  81%  10 
Ferrari, 2005  1236  51(4.1%)  13.72%  10±1.9 
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risk for bleeding or for reoperation due to postoperative 
haemorrhage
  [38], even if aspirin is associated with 
clopidogrel and not discontinued within 2 days of surgery 
(no differences with the discontinuation more than 6 days 
before surgery or between 2 and 5 days before surgery) [39]. 
Moreover, some articles have associated preoperative aspirin 
maintenance with a decreased risk of mortality in CABG 
patients without significant increase in haemorrhage, blood 
product requirements, or related morbidities [40], even with 
aspirin usage within the 5 days preceding surgery
 [41]. 
  Thus, some surgical and patients characteristics as older 
age, smaller body mass index, non-elective cases, 5 or more 
distal anastomosis are more important risk factors for re-
exploration for bleeding after CABG than aspirin ingestion, 
which is consistent with other previous studies [42, 43]. 
  The other common drugs used as antiplatalet agent are 
thienopyridines that antagonist irreversibly the platelet 
adenosine diphosphate. It has showed to increase bleeding 
after CABG in many articles
  [44-48], although there is 
another report in which the maintenance of clopidogrel does 
not increase bleeding or transfusion requirements [49]. The 
optimal waiting period after last clopidogrel administration 
is not known but appears to be at least 5 days before CABG 
[50]; if the patient need to be antiaggregated near before 
cardiac surgery, probably the best option is to use low-dose 
aspirin perioperatively, once clopidogrel has been discon-
tinued [51]. Finally, it has been published that a combined 
preoperative treatment with heparin infusion could prevent 
the increased blood loss associated to the administration of 
clopidogrel, which may have been attributable to a conser-
vation of coagulation factors, as evidenced by the increased 
plasma fibrinogen concentrations with combined prophy-
lactic treatment [52]. 
  Other drugs that have become increasingly common are 
the intravenous GP IIb/IIIa platelet receptor antagonist 
(tirofiban, eptifibate and abciximab). While eptifibatide and 
tirofiban have a competitive binding and are rapidly cleared, 
with an almost recovered platelet function in about 4 hours 
[53], abciximab causes prolonged and irreversible effect, 
with inhibition of platelet function and aggregation lasting 
24-48 hours [53]. Transfusion of platelets rapidly reverses 
the inhibitory effects of abciximab [54], but it is of very little 
utility during infusion or suddenly after eptifibatide or 
tirofiban. No data are available in the literature on the impact 
of tirofiban or eptifibatide treatment on emergency CABG; 
however their short half-life and short-lasting action after 
stopping the infusion is a potential advantage for the 
performance of CABG with reduced risk of bleeding [55-
58], so no delay in surgery has been recommended [59]. In 
patients treated with abciximab, delaying emergency or 
urgent CABG for 12 hours has been recommend [59, 60], 
but other authors suggest rapid discontinuation of abciximab 
infusion and undelayed intervention [61, 62]. In any case, 
platelet transfusion should be considered only when 
increased bleeding is encountered (not prophylactically), and 
only after cessation of cardiopulmonary bypass [63]. 
4.1. Methods to Avoid Bleeding 
  In cardiac surgery, we should also take care of a variety 
of methods intended to minimize perioperative transfusion: 
preoperative autologous donation, intra- and postoperative 
cell salvage, and the use of drugs, such as aprotinin (a 
protease inhibitor), desmopressin (that induces the release of 
factor VIIIvW) and tranexamic acid (TXA) and epsilon-
aminocarproic acid (EACA) (that mainly inhibit plasmin 
binding to fibrin).  
  Many studies have shown that aprotinin decreased the 
number of allogenic transfusions after cardiac surgery and 
the proportion of patients requiring reoperation because of 
bleeding [64]. Recent publications, however, have 
questioned the safety of this agent, reporting not only an 
increase in renal impairment but an increased risk of long-
term mortality following CABG surgery [65-67]. The FDA 
and the EMEA have recently suspended its use, pending of a 
complete analysis of a randomized prospective trial in 
Canada (BART trial), which has shown similar results in 
terms of mortality. 
  Desmopressin has not shown a statistically significant 
effect on reducing the proportion of patients receiving 
transfusion after CABG [64], but its efficacy seemed to vary 
depending on the use of aspirin. While some authors have 
shown that desmopressin reduced the postoperative blood 
loss and the transfusion requirements in patients treated with 
aspirin within 7 to 5 days before surgery compared to 
placebo [68-70], no effect was found in patients treated 
within 2 days before CABG [71]. 
  The TXA decreases the portion of patients receiving 
allogenic blood, but has not statistically significant effect on 
reoperations because of bleeding [64], both in on- and in off-
pump surgery [72]. This effect is no consistent in all the 
studies, excluding patients with APD, prophylactic use of 
TXA did not result in any significant decrease in 
postoperative bleeding in one study [73], but reduced 
postoperative bleeding and fibrinolysis in another [74]. In 
patients treated with aspirin, the administration of a single 
dose of TXA (30 mg/kg) immediately before cardio-
pulmonary bypass significantly reduced postoperative 
bleeding and inhibited fibrinolysis [75].  
  There are very few studies with EACA that have not 
shown any statistically significant effect [64]. 
4.2. Monitors of Platelet Function Perioperatively  
  The current standard of care for perioperative coagulation 
monitoring consists of a platelet count and prothrombin (PT) 
and activated partial thromboplastin (aPTT) times, omitting 
platelet function. However, these routine tests are insensitive 
predictors of bleeding and perioperative changes in platelet 
count shows poor correlation with changes in platelet 
function [76]. It would be helpful in the perioperative 
management of APD to have a haemostatic test to identify 
the patients at bleeding risk because of platelet dysfunction 
related with the administration of any APD.  
  Several tests could be used to assess the platelet function. 
Optical platelet aggregometry is considered at present the 
reference assay for diagnosis of platelet disorders [12], 
although it is not completely standardized, the laboratory 
work up is complex and it is not possible to be performed 
immediately before the surgery. The Platelet Function 
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measuring the closure time taken for a platelet plug to 
occlude an aperture in a membrane impregnated with 
collagen and epinephrine or ADP [77]; ASA and clopidogrel 
have been shown to prolong this closure time, but without 
evident correlation with a perioperative bleeding. The 
Plateletworks
TM analyser measures the percentage of 
aggregation of whole blood before and after the exposure to 
ADP; its results are contradictory when compared with 
optical aggregometry: good correlation for clopidogrel [78] 
but of limited use for ASA [79]. Thromboelastogrphy (TEG) 
is a whole blood coagulation monitor, which can 
demonstrate the alteration of platelet aggregation, but is 
unable to detect the defects that occur with ASA or 
demonstrate the ADP blockade caused by clopidogrel. 
  Unfortunately any of these tests has good correlation 
with perioperative bleeding and further clinical inves-
tigations are necessary in this field, although they can help 
us to reduce the rate of reoperation for bleeding (TEG), in 
part by helping to differentiate surgical from nonsurgical 
bleeding [80], or to improve appropriate platelet transfusion 
(PFA-100) [81]. 
5. GUIDELINES AND RECOMMENDATIONS 
  The management of patients under the effect of 
antiaggregant agents scheduled for cardiac surgery is a major 
topic of interest and concern for all perioperative caregivers. 
Many recommendations could be found in the available 
published papers [8, 13, 14, 36, 37, 51, 82-85] and they 
could be summarized as follows: 
1. Patient Treated with Aspirin 
•  Aspirin should be maintained in patients at high risk for 
arterial thrombotic complications. The optimal dose of 
aspirin ranges between 75 and 325 mg and in the 
perioperative period, in the majority of patients, it would 
be enough the maintenance of low-dose of aspirin.  
•  In the case of high risk of bleeding, some drugs that 
decrease postoperative bleeding, as TXA or EACA 
(with limited evidence to support the use of one agent 
over the other) could be used; desmopresine might be 
considered preoperatively only in patients with acquired 
or inherited defects in primary haemostasis detected by 
abnormal point-of-care test, as PFA-100. 
2. Patient Treated with Clopidogrel 
•  If the patient is on treatment with clopidogrel and needs 
to be antiaggregated near before cardiac surgery, 
probably the best option is to discontinue clopidogrel (at 
least 5 days before surgery) and use low-dose aspirin 
perioperatively (75-125 mg daily). 
•  Dual antiplatelet therapy is associated with too high 
bleeding risk. If it is mandatory to maintain this protocol 
before surgery (probably only in patients with a drug-
eluting stent implanted less than 12 months ago), and 
because of the concerns about premature discontinuation 
of clopidogrel in these very high thrombotic risk 
patients, several algorhythms have been proposed, 
including the administration of an intravenous 
glycoprotein IIb/IIIa inhibitor or unfractionated heparin 
as “bridging therapy”. At present, there is no enough 
evidence-based date to support this strategy. 
3. Patient Treated with GP IIb/IIIa Inhibitor 
•  In emergency surgery, if the patient is under the effect 
of a glycoprotein IIb/IIIa inhibitor, it might be 
considered the platelet transfusion (mainly if it is 
abciximab) if there is too much bleeding; due to the 
short-acting time of eptifibatide or tirofiban, the delay of 
surgery is not recommended in the case of previous 
administration of them. 
4. Postoperative Treatment 
•  If aspirin therapy has been interrupted before surgery, it 
should be administered early after surgery, always 
within 48 hours after CABG, and preferably within 6 
hours after surgery. Dose ranges between 150-325 
mg/day; optimal benefit could be reach with 325 
mg/day, at least the first year. 
•  There is no specific recommendation for resuming 
clopidogrel after surgery, and it seems to have no 
superiority over aspirin; if it is indicated instead of 
aspirin, the timing for its administration could be the 
same as for aspirin, but it is not recommended a loading 
dose (300-600 mg) if first administration is close after 
surgery. 
5. Others 
•  Blood salvage techniques use must be encouraged, as 
the devices that conserve blood (intraoperative blood 
salvage) or the use of autologous blood predonation or 
normovolaemic haemodilution. 
•  Platelet transfusion is not indicated as prophylaxis to 
avoid bleeding, even if the patient is under the effect of 
aspirin or clopidogrel, and its administration must be 
reserved if necessary to control excessive bleeding. 
•  It is necessary an optimal preparation of the patient, 
avoiding anaemia  stimulating the administration of 
drugs that increase preoperative blood volume, as 
erythro-poietin in combination with iron. 
•  Several guidelines recommend a multimodality app-
roach to blood conservation with the setting-up of 
consensus algorhythms and point-of-care testing. 
6. CONCLUSIONS 
  The handicap of management of antiplatelet agents in the 
perioperative period of cardiac surgery requires close colla-
boration between cardiologists, surgeons and anaesthesio-
logists. It is necessary to avoid thrombotic complications 
maintaining the antiaggregation, but balancing bleeding 
complications. 
  Patients treated with long-term APD could be at risk for 
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there are any other outstanding variable as indicator of risk: 
advanced age, preoperative anaemia, reoperative o complex 
procedures, emergency operations or non-cardiac patient co-
morbidities. If the patient is under the effect of one or more 
of these drugs the associated bleeding risk might be carefully 
balanced and an alternative antiaggregation protocol could 
be considered. Moreover, the drugs to minimize bleeding 
could play an important role and might be in consideration.  
  The decision to stop the APD some days before surgery 
faces up to the decision to maintain the treatment up to 
surgery. The choice for one or the other option should be 
based on the individual balance between the risk to develop 
any cardiovascular event if the APD has been withdrawn and 
the complications associated as result of the major bleeding 
if the APD has been maintained until the day of the surgery. 
  Summarising both possibilities and the comments stated 
above, we know that clopidogrel maintenance prior to 
cardiac surgery is associated with a more blood product 
usage, a 2-5 fold increase in the risk of re-exploration and 
30-100% increase in the chest drain blood loss. The 
withdrawal of clopidogrel prior to surgery, between 5 and 7 
days, could be associated with a little increase of the risk of 
myocardial infarction, estimated around 1% while the patient 
is waiting for surgery [84]. Between patients under aspirin, 
its withdrawal 2-3 days before surgery could reduce 
perioperative blood loss, risk for transfusion and reoperation 
for bleeding. This practice seems safe for patients without 
acute coronary syndromes, but for urgent cardiac surgery, 
the risk of perioperative infarction is higher and the balance 
is favourable to the maintenance of aspirin up to the day of 
surgery. 
  So, for patients scheduled for CABG, the recommen-
dation is to stop clopidogrel at least 5 days and, preferably, 
10 days prior to surgery to minimize blood loss. In the case 
of aspirin, the recommendation is to maintain it up to surgery 
and beyond the time of surgery. But in the case of patients, 
who are not at high risk for cardiac events, the routine 
recommendation is to stop aspirin or clopidogrel prior to 
surgery because of risk of bleeding and morbi-mortality 
associated in these patients [85]. 
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